Market Place
Sourcing Support
Kadcyla Is the First Targeted Therapy to Show OS Benefit in Breast Cancer
09 Dec 2023 //
BUSINESSWIRE
Seagen says Tukysa combo hits main goal in Phase III breast cancer study
17 Aug 2023 //
BUSINESSWIRE
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial
07 Dec 2022 //
BUSINESSWIRE
ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%
07 Dec 2022 //
BUSINESSWIRE
ENHERTU Additional Analyses Reinforce Ground-breaking Efficacy in Breast Cancer
09 Dec 2021 //
BUSINESSWIRE
Daiichi Sankyo to Present New Breast Cancer Data at 2021 SABCS
01 Dec 2021 //
BUSINESSWIRE
Hope Soars at ESMO 2021 for Breast Cancer Treatments
20 Sep 2021 //
BIOSPACE
AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data
13 May 2020 //
BUSINESSWIRE
NICE backs Roche`s Kadcyla for HER2-positive early breast cancer
11 May 2020 //
PHARMATIMES
NICE draft guidance recommends new treatment option for people breast cancer
07 May 2020 //
NICE
Samsung Bioepis Announces US Launch of ONTRUZANT® (trastuzumab-dttb)
15 Apr 2020 //
BUSINESSWIRE
Roche wins approval for cancer drug Kadcyla in fast-growing China market
24 Jan 2020 //
REUTERS
WindMIL Therapeutics Announces Research Collaboration with Bristol-Myers Squibb
19 Dec 2019 //
GLOBE NEWSWIRE
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
18 Dec 2019 //
PMLIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.